Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles
- PMID: 17181168
- DOI: 10.1021/jm060957y
Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles
Abstract
In an effort to develop potent new antituberculosis agents that would be effective against both drug-susceptible and drug-resistant strains of Mycobacterium tuberculosis, we prepared a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles substituted at the 2-position with various phenoxymethyl groups and a methyl group and investigated the in vitro and in vivo activity of these compounds. Several of these derivatives showed potent in vitro and in vivo activity, and compound 19 (OPC-67683) in particular displayed excellent in vitro activity against both drug-susceptible and drug-resistant strains of M. tuberculosis H37Rv (MIC = 0.006 microg/mL) and dose-dependent and significant in vivo efficacy at lower oral doses than rifampicin in mouse models infected with M. tuberculosis Kurono. The synthesis and structure-activity relationships of these new compounds are presented.
Similar articles
-
Synthesis of novel [1,2]-diamines with antituberculosis activity.Bioorg Med Chem Lett. 2009 Sep 15;19(18):5372-5. doi: 10.1016/j.bmcl.2009.07.126. Epub 2009 Aug 6. Bioorg Med Chem Lett. 2009. PMID: 19682895
-
1,3-Azoles from ortho-naphthoquinones: synthesis of aryl substituted imidazoles and oxazoles and their potent activity against Mycobacterium tuberculosis.Bioorg Med Chem. 2012 Nov 1;20(21):6482-8. doi: 10.1016/j.bmc.2012.08.041. Epub 2012 Aug 31. Bioorg Med Chem. 2012. PMID: 23000294
-
3'-bromo analogues of pyrimidine nucleosides as a new class of potent inhibitors of Mycobacterium tuberculosis.J Med Chem. 2010 May 27;53(10):4130-40. doi: 10.1021/jm100165w. J Med Chem. 2010. PMID: 20420370
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
[Active drugs against Mycobacterium tuberculosis].Enferm Infecc Microbiol Clin. 2009 Oct;27(8):474-80. doi: 10.1016/j.eimc.2009.06.010. Epub 2009 Sep 18. Enferm Infecc Microbiol Clin. 2009. PMID: 19766360 Review. Spanish.
Cited by
-
Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children.Front Cell Infect Microbiol. 2023 Jun 13;13:1183597. doi: 10.3389/fcimb.2023.1183597. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37384221 Free PMC article. Review.
-
Extensively Drug-Resistant Tuberculosis: A Sign of the Times and an Impetus for Antimicrobial Discovery.Pharmaceuticals (Basel). 2010 Jul 1;3(7):2268-2290. doi: 10.3390/ph3072268. Pharmaceuticals (Basel). 2010. PMID: 21170297 Free PMC article.
-
Prediction of Human Pharmacokinetic Profiles of the Antituberculosis Drug Delamanid from Nonclinical Data: Potential Therapeutic Value against Extrapulmonary Tuberculosis.Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0257120. doi: 10.1128/AAC.02571-20. Epub 2021 Jul 16. Antimicrob Agents Chemother. 2021. PMID: 34097484 Free PMC article.
-
Pentacyclic nitrofurans with in vivo efficacy and activity against nonreplicating Mycobacterium tuberculosis.PLoS One. 2014 Feb 5;9(2):e87909. doi: 10.1371/journal.pone.0087909. eCollection 2014. PLoS One. 2014. PMID: 24505329 Free PMC article.
-
Development of a Scalable Process for the Synthesis of DNDI-VL-2098: A Potential Preclinical Drug Candidate for the Treatment of Visceral Leishmaniasis.Org Process Res Dev. 2017 Jan 20;21(1):52-59. doi: 10.1021/acs.oprd.6b00331. Epub 2016 Dec 6. Org Process Res Dev. 2017. PMID: 28539754 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical